VIDA SIGNIFICANT ASTHMA EXACERBATION (Visits 2-10, 88 and 90-92)

Similar documents
2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64)

MEDICAL ASSISTANCE BULLETIN

Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD.

Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation

Recommended Component: Assure Immediate Access to Medications as Prescribed

Supplementary Online Content

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Disclosure Statement. Epidemiological Data

2. Does the patient have chronic urticaria? Y N

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

DESCRIPTION: Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication

Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Drug Class Review on Beta 2 -Agonists

MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C

CME/CE POSTTEST CME/CE QUESTIONS

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

Student Paper PHARMACY PRACTICE. Keywords: asthma, inhalers, patient education

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices

ASSOCIATION OF ASTHMA CONTROL WITH HEALTH CARE UTILIZATION A PROSPECTIVE EVALUATION

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Long Term Care Formulary RS -29

2015 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients aged 18 and older)

Adult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices

USAID Health Care Improvement Project

Asthma Please complete packet and return to nurse at child s school

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015

Estimated date of first patient enrolled Q III/IV Estimated date of last patient completed Q3 2015

SYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.

PATIENT INFORMATION FORM

Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs

2014 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients aged 18 and older)

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.

2013 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients 18 and older)

Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Subject: Bronchial Thermoplasty

Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year,

«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients»

Type of intervention Treatment. Economic study type Cost-effectiveness analysis.

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Pharmacy Medical Policy IgE Receptor Binding Inhibitors

Learning the Asthma Guidelines by Case Studies

ASTRAZENECA v GLAXOSMITHKLINE

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

Do We Need Biologics in Pediatric Asthma Management?

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Asthma Assessment & Review

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Serious Adverse Event (SAE) Form Clinical Trials

Treatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health.

Individual Study Table Referring to Part of the Dossier. Volume:

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Title of Project: NHS Dumfries & Galloway Respiratory Bundle Asthma: Bronchodilator Overuse Review April 2015

Study Investigators/Centers: GSK sponsored studies MEA112997, MEA115588, and MEA and a proof of concept investigator sponsored study CRT110184

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction

Management of Asthma in the United States: Where Do We Stand?

EXACERBATION ASSESSMENT FORM

Update on management of respiratory symptoms. Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT

Pharmacy Prior Authorization

EXACERBATION ASSESSMENT FORM

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

CHARM ASTHMA TREATMENT GUIDELINE

Secondary Outcome/Efficacy Variable(s):

Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives

Methacholine versus Mannitol Challenge in the Evaluation of Asthma Clinical applications of methacholine and mannitol challenges

Serious Adverse Event (SAE) Form Clinical Trials

Improving the Management of Asthma to Improve Patient Adherence and Outcomes

Daclizumab improves asthma control in patients with moderate to. severe persistent asthma: A randomized, controlled trial

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

SYNOPSIS. Date 15 June 2004

Chronic obstructive pulmonary disease (COPD) is characterized

Predicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa

SYNOPSIS. Study centres This was a multicentre study conducted in 53 centres in Sweden.

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

2017 Blue Cross and Blue Shield of Louisiana

Paediatric Public Assessment Report EU Work sharing Procedure - Assessment of Paediatric data. Pulmicort Turbuhaler. Powder for inhalation.

OUTCOMES SUMMARY REPORT

Presented by the California Academy of Family Physicians 2013/California Academy of Family Physicians

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012

Asthma 2015: Establishing and Maintaining Control

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

2014 Physician Quality Reporting System Data Collection Form: Cataracts (for patients aged 18 and older)

Meenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar

Priority Health Medicare prior authorization form Fax completed form to: toll free, or

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

Pain: Facility Assessment Checklists

2013 National Treatment Survey. Immune Deficiency Foundation

2. Does the patient have a diagnosis of Crohn s disease? Y N

Transcription:

VIDA SIGNIFICANT ASTHMA EXACERBATION (Visits 2-10, 88 and 90-92) Part. ID: - - Part. Initials: Visit: Visit Date: / / 20 Coordinator ID: (Coordinator Completed) For participants who meet treatment failure criteria, complete this form to assess for the occurrence of a significant asthma exacerbation. Submit this form to the DCC only if the participant meets exacerbation criteria. 1. Did the participant fail to respond within 48 hours to the treatment failure rescue algorithm? 2. Did the participant use at least 16 puffs of PRN levalbuterol per 24 hours for a period of 48 hours? (Do not complete Q3 at Visits 2 and 3) 3. Did the participant experience prebronchodilator FEV 1 values < 50% of the baseline prebronchodilator value obtained at Visit 3 on two consecutive spirometric determinations made on different days? (Do not complete Q4 at Visits 2 and 3) 4. Did the participant experience prebronchodilator FEV 1 values < 40% of predicted on two consecutive spirometric determinations made on different days? (1000) 1 Yes 0 No (1010) 1 Yes 0 No (1020) 1 Yes 0 No 9 Not evaluated (1030) 1 Yes 0 No 9 Not evaluated 5. Did the study or treating physician prescribe the participant (1035) oral/parenteral corticosteroids for the treatment of his/her 1 Yes 0 No asthma? If YES, record the oral/parenteral corticosteroids on the Concomitant Medications for Asthma/Allergy and Adverse Events (CMED) form. 6. Did the participant experience a significant asthma exacerbation in the opinion of the study investigator or personal physician? (1040) 1 Yes 0 No 7. Did the participant experience a significant asthma exacerbation? If any of the shaded boxes in Q1-Q6 is filled in, the participant experienced an asthma exacerbation. (1050) 1 Yes 0 No If YES, complete Q8 and record the exacerbation on the Clinical Adverse Events (AECLIN) form using ICD-9 code 493.92. If NO, STOP HERE and continue with remaining visit procedures. Do NOT submit this form to the DCC. 8. Date exacerbation conditions were met (1060) / / 20 MM DD YYYY COMMENTS: (6000) 05/08/2012 version2.0 Page 1 of 1 *P1_sigex*

VIDA TREATMENT FAILURE CHECKLIST Part. ID: - - Part. Initials: Visit: Visit Date: / / 20 Coordinator ID: (Coordinator Completed) Complete this form at all visits from Visit 3 until the end of the study to assess the participant for treatment failure criteria. If a participant experiences treatment failure during the run-in and is seen prior to Visit 3, complete a single form using visit number 2. (Visits 90-92 Only) 1. Complete the number of the last regular visit completed (1000) 2. Did the participant experience a fall in prebronchodilator PEF to < 65% of baseline on two out of three consecutive, scheduled (AM or PM) measurements? Refer to the VIDA Baseline PEF and Rescue Use Values (P1_BASELINE) form. 3. Did the participant experience an increase in rescue levalbuterol use of 8 or more puffs per 24 hours over baseline use for a period of 48 hours? Refer to the VIDA Baseline PEF and Rescue Use Values (P1_BASELINE) form. (1010) 1 Yes 0 No (1020) 1 Yes 0 No (Do not complete Q4 at Visits 2 and 3) 4. Did the participant experience prebronchodilator FEV 1 values < 80% of the baseline prebronchodilator value obtained at Visit 3 on two consecutive spirometric determinations made on different days? (1030) 1 Yes 0 No 9 Not evaluated If the participant experienced a prebronchodilator FEV 1 value < 80% of the baseline value obtained at Visit 3, but he/she was not evaluated a second time, select Not Evaluated. 5. Did the study or treating physician prescribe the participant (1040) additional inhaled corticosteroids or oral/parenteral 1 Yes 0 No corticosteroids for the treatment of his/her asthma? If YES, and oral/parenteral corticosteroids or non-study inhaled steroids were used, record them on the Concomitant Medications for Asthma/Allergy and Adverse Events (CMED) form. If YES, and oral/parenteral corticosteroids were used, complete a VIDA Significant Asthma Exacerbation (P1_SIGEX) form. 6. Did the participant require emergency treatment at a (1050) medical facility that was related to, or complicated by, 1 Yes 0 No his/her asthma and that resulted in systemic corticosteroid treatment or hospitalization for an acute asthma exacerbation? If YES, and the participant was hospitalized, complete a Serious Adverse Event Reporting Form (SERIOUS). If YES, and systemic corticosteroid treatment was received, record medications on the Concomitant Medications for Asthma/Allergy and Adverse Events (CMED) form. 05/02/2012 version1.1 Page 1 of 2 *P1_TXFAIL_chk*

TREATMENT FAILURE CHECKLIST Part. ID: - - Visit: 7. Did the participant refuse to continue study drugs because of lack of satisfaction with treatment? 8. Based on clinical judgment, did the physician deem this participant a treatment failure for safety reasons? 9. Did the participant experience a significant asthma exacerbation? If YES, complete the VIDA Significant Asthma Exacerbation (P1_SIGEX) form. (1060) 1 Yes 0 No (1070) 1 Yes 0 No (1080) 1 Yes 0 No 10. Did the participant experience a treatment failure? (1090) 1 Yes 0 No If any of the shaded boxes in Q2-Q9 is filled in, the participant experienced a treatment failure. If YES, complete the rest of this form and record the treatment failure on the Clinical Adverse Events (AECLIN) form using ICD-9 code 000.00. Also, complete a Treatment Failure Information (P1_TXFAIL) form. If NO, STOP HERE and continue with remaining visit procedures. 11. Date treatment failure conditions were met (1100) / / 20 MM DD YYYY COMMENTS: (6000) 05/02/2012 version1.1 Page 2 of 2 *P1_TXFAIL_CHK*